Clinical Trial Update: Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) [Phase 2]

View source ↗

Summary

Phase 2 study of DS-1062a in advanced or metastatic non-small cell lung cancer with actionable genomic alterations has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DS-1062a (datopotamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-04-03